Future biologic targets for IBD: potentials and pitfalls.
about
Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease.Drosophila melanogaster as a model for human intestinal infection and pathology.Current and emerging drugs for the treatment of inflammatory bowel disease.Dietary grape seed extract ameliorates symptoms of inflammatory bowel disease in IL10-deficient miceDysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers.Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease.An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease.Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease.Immune markers and differential signaling networks in ulcerative colitis and Crohn's diseaseMetagenomics and personalized medicine.Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis.Distinct NF-κB and MAPK Activation Thresholds Uncouple Steady-State Microbe Sensing from Anti-pathogen Inflammatory Responses.Future therapeutic approaches for inflammatory bowel diseases.Is metabolic stress a common denominator in inflammatory bowel disease?Targeting T-cell migration in inflammatory bowel disease.Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease.Gene expression profiles of ileal inflammatory bowel disease correlate with disease phenotype and advance understanding of its immunopathogenesis.Nanoparticle-based imaging of inflammatory bowel disease.N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies.MicroRNA-orchestrated pathophysiologic control in gut homeostasis and inflammationMuc17 protects intestinal epithelial cells from enteroinvasive E. coli infection by promoting epithelial barrier integrity.Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease.IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cellsOpposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice.TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation.A novel algorithm for finding optimal driver nodes to target control complex networks and its applications for drug targets identification.An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.The Dynamics of Interleukin-10-Afforded Protection during Dextran Sulfate Sodium-Induced Colitis.Interleukin 27 is up-regulated in patients with active inflammatory bowel disease
P2860
Q30414837-D9283391-174E-41AA-827F-96FFC84B52B8Q34458779-9022ABF0-A6FC-472A-B760-48AB56102AB8Q34883210-76F99BB2-F212-48B8-842A-0E2C02A3DDF8Q34959929-2E2CFEA0-0662-4E53-982F-C5764E5727A7Q34980836-94629B8F-4600-4243-97A1-78C807DC21B2Q35001662-979296F7-E9FB-4E3D-82C3-BBA4BCCD03CDQ35586236-B4ED714A-6E41-4D88-8E52-BA36FC84A1EDQ35994628-FB98CA63-7DBF-4F2D-9B46-26468594DB7AQ36125752-BB9A0D49-7A37-4982-8A41-4CEEFAD1C9D0Q36202077-DD311B1F-096B-461A-B7D2-0E31D2B315C8Q36837922-735A4A00-BF76-47BB-ADE2-98538198CA59Q37033724-26E3F63E-B799-4BBB-87BA-071E02EFF2FEQ37870435-A257BEFF-CE4B-465E-A0ED-23003B3311F5Q37914788-93B0E620-9B91-4060-A668-1D43AC3E545FQ38040430-014E720C-C437-48AF-BA3F-4259C7EEF0BAQ38125275-3333539D-0013-4A12-8CB5-D0884D93A26EQ38484856-4EFB196F-2505-4581-B8AF-572A2D3D44E4Q38587041-4BE5786E-2E37-485E-8E31-A8A6D5385428Q38599291-7EAB1E41-33D2-41B3-A614-9066F0233119Q38750548-BC71CEFF-3D7C-4E35-A520-E84C5A15FFE1Q38753541-CCC987FC-31EE-4F0A-829C-E9FE296A9D32Q39577860-DE9A5E03-1950-46A0-BB67-93A12EC8F77BQ41222715-DF57921E-CADC-47BF-B9B5-7F007CF24679Q42321500-1333B1A0-D7FB-4A65-8574-1B0411E883E7Q46413941-47CFECD7-279E-429B-82F4-F24484F2AE81Q46700871-DFF4924C-25CA-45E7-A8EB-9A341D4EC838Q47557236-121E7735-A8EE-41D0-8294-2A844C5A77EFQ48939479-B67FDEE5-FE13-4C46-B47F-5855C00D9C04Q52653104-2502512A-F7C4-4677-868B-8F34DABB3F99Q57735511-9042501B-1409-4D46-8B55-82518D767DA5
P2860
Future biologic targets for IBD: potentials and pitfalls.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Future biologic targets for IBD: potentials and pitfalls.
@en
Future biologic targets for IBD: potentials and pitfalls.
@nl
type
label
Future biologic targets for IBD: potentials and pitfalls.
@en
Future biologic targets for IBD: potentials and pitfalls.
@nl
prefLabel
Future biologic targets for IBD: potentials and pitfalls.
@en
Future biologic targets for IBD: potentials and pitfalls.
@nl
P1476
Future biologic targets for IBD: potentials and pitfalls.
@en
P2093
Gil Y Melmed
Stephan R Targan
P2888
P304
P356
10.1038/NRGASTRO.2009.218
P407
P577
2010-02-01T00:00:00Z
P6179
1018880982